Yvo de Beer

Therapeutic drug monitoring of everolimus using the dried blood spot method in combination with liquid chromatography–mass spectrometry

J. van der Heijden, Yvo de Beer, K. Hoogtanders et al. · Journal of Pharmaceutical and Biomedical Analysis · 2008 · 117 citations

Therapeutic Drug Monitoring, Liquid Chromatography–mass Spectrometry, Drug Discovery +12

Validation of an analytical method using HPLC–MS/MS to quantify osimertinib in human plasma and supplementary stability results

Ard van Veelen, Robin M.J.M. van Geel, Yvo de Beer et al. · Biomedical Chromatography · 2019 · 32 citations · Full text

Development and validation of an analytical method using UPLC–MS/MS to quantify everolimus in dried blood spots in the oncology setting

Lotte M. Knapen, Yvo de Beer, Roger J. M. Brüggemann et al. · Journal of Pharmaceutical and Biomedical Analysis · 2017 · 31 citations · Full text

Oncology, Dried Blood Spots, Medicine +10

Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run

Ard van Veelen, Robin M.J.M. van Geel, Roy Schoufs et al. · Biomedical Chromatography · 2021 · 26 citations · Full text